Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and DNA Damage Response (DDR) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHD1L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHD1L Recombinant Protein (Full-Length & Macrodomain) High purity (>95%), Endotoxin controlled. Sequence Verified. Available in wild-type and ATPase-dead mutant forms. |
View CHD1L Products |
| Gene Delivery | CHD1L Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View CHD1L Products |
| Benchmark Ab | Anti-CHD1L Recombinant Antibody Recombinant positive control antibody verified for Western Blot, IP, and IHC applications. |
View CHD1L Products |
| Validator | CHD1L siRNA Set Target-specific siRNA pool for target knockdown and functional validation. |
View CHD1L Products |
| Related Target A | PARP1 Crucial upstream activator of CHD1L; CHD1L (ALC1) is recruited to DNA damage sites via PARP1-mediated PARylation. |
View PARP1 Products |
| Related Target B | ATR Key kinase in the DNA damage response pathway; synergistic inhibition with CHD1L blocks alternative repair pathways. |
View ATR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting PARP1-Dependent Activation | Human recombinant CHD1L wild-type and mutated proteins strictly verified for theoretical MW and sequence integrity, facilitating robust in vitro PAR-binding assays. |
| Selectivity Screening Against SNF2 Family | High-purity homologous chromatin remodeler proteins available to establish counter-screening panels. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated positive controls included in the portfolio. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target-specific knockdown verification in cellular phenotypic assays. |
Live CHD1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHD1L (also known as ALC1) therapeutics is intensifying, with major players shifting focus from traditional DNA-damaging chemotherapies to targeted synthetic lethality strategies. As first-generation PARP inhibitors encounter resistance, the next wave of R&&D is targeting CHD1L to overcome homologous recombination deficiency (HRD) bypass and restore sensitivity to DNA-damaging agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (ATPase) | Oncology-focused Biotechs, Academic Lead-Finders | Ovarian Cancer, Breast Cancer, HCC | In vitro ATPase activity assays (Requires high-purity, active recombinant CHD1L and negative control mutants) |
| Small Molecule (Macrodomain Disruptor) | DDR-focused Pharma | PARP-inhibitor Resistant Tumors | PAR-binding assays (Requires sequence-verified CHD1L Macrodomain fragment) |
| Combination Therapies (siRNA/Lentivirus) | Translational Research Institutes | Solid Tumors with HRD | Target knockdown and rescue validation (Requires high-titer Lentivirus and validated siRNA sets) |